

Express Mail No.: EL 500 575 025 US



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10624-049-999

APPLICATION NO.

10/004,642

APPLICANT

Kois et al.

FILING DATE

December 4, 2001

GROUP

1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,788,195	11/29/88	Torley et al.			
	AB	4,876,252	10/24/89	Torley et al.			
	AC	4,966,622	10/30/90	Rempfler et al.			
	AD	4,973,690	11/27/90	Rempfler et al.			
	AE	5,159,078	10/27/92	Rempfler et al.			
	AF	5,166,047	11/24/92	Hioki et al.			
	AG	5,262,527	11/16/93	Gregory et al.			
	AH	5,489,505	2/6/96	Kato et al.			
	AI	5,516,775	5/14/96	Zimmerman et al.			
	AJ	5,527,914	6/18/96	Hioli et al.			
	AK	5,942,384	8/24/99	Arai et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL	WO 98/18782	5/7/98	PCT				
	AM	WO 01/14375	3/1/01	PCT				
	AN	WO 01/27089	4/19/01	PCT				
	AO	WO 00/43373	7/27/00	PCT				
	AP	WO 98/20003	5/14/98	PCT				
	AQ	WO 93/08167	4/29/93	PCT				
	AR	WO 01/12621	2/22/01	PCT				
	AS	WO 00/75118	12/14/00	PCT				
	AT	WO 00/39101	7/6/00	PCT				
	AU	WO 00/56738	9/28/00	PCT				
	AV	WO 00/15657	3/23/00	PCT				
	AW	WO 01/91749	12/6/01	PCT				
	AX	WO 00/12486	3/9/00	PCT				
	AY	WO 01/29009	4/26/01	PCT				
	AZ	WO 01/23382	4/5/01	PCT				
	BA	WO 00/78731	12/28/00	PCT				
	BB	WO 00/33844	6/15/00	PCT				
	BC	WO 00/31067	6/2/00	PCT				
	BD	WO 99/63821	12/16/99	PCT				

BE	WO 99/01439	1/14/99	PCT				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
BG	Aspenstrom et al., 1996, "Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome", <i>Curr. Biol.</i> 6:70-77						
BH	Baeuerle and Baichwal, 1997, "NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules", <i>Advances in Immunology</i> 65:111-137						
BI	Beg et al., 1995, "Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B", <i>Nature</i> 376(6536):167-70						
BJ	Bohrer et al., 1997, "Role of NFkappaB in the mortality of sepsis.", <i>J. Clin. Inv.</i> 100:972-985						
BK	Brand et al., 1997, "Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion", <i>J Clin Inv.</i> 97:1715-1722						
BL	Burke et al., 1999, "Peptides corresponding to the N and C termini of IkappaB-alpha, -beta, and -epsilon as probes of the two catalytic subunits of IkappaB kinase, IKK-1 and IKK-2", <i>Journal of Biological Chemistry</i> 274:36146-36152						
BM	Chen et al., 1996, "Activation and inhibition of the AP-1 complex in human breast cancer cells", <i>Mol. Carcinogenesis</i> 15:215-226						
BN	Cramer et al., 1999, "A firm hand on NFkappaB: structures of the IkappaBalpha-NFkappaB complex", <i>Structure</i> 7:R1-R6						
BO	Deacon et al., 1999, "MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases", <i>J. Biol. Chem.</i> 274:16604-16610						
BP	Delhase et al., 1999, "Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation", <i>Science</i> 284:309-313						
BQ	Dong et al., 1998, "Defective T cell differentiation in the absence of Jnk1", <i>Science</i> 282:2092-2095						
BR	Faris et al., 1996, "Regulation of interleukin-2 transcription by inducible stable expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in Jurkat T cells", <i>J. Biol. Chem.</i> 271:27366-27373						
BS	Gosset et al., 1995, "Expression of E-selectin, ICAM-1 and VCAM-1 on bronchial biopsies from allergic and non-allergic asthmatic patients", <i>Int Arch Allergy Immunol.</i> 106:69-77						
BT	Gum et al., 1997, "Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades", <i>Oncogene</i> 14:1481-1493						
BU	Han et al., 1999, "Jun N-terminal kinase in rheumatoid arthritis", <i>J. Pharm. Exp. Therap.</i> 291:124-130						
BV	Hibi et al., 1993, "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain", <i>M. Genes Dev.</i> 7:2135-2148						
BW	Hu et al., 1999, "Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase", <i>Science</i> 284:316-320						
BX	Ishizuka et al., 1997, "Mast cell tumor necrosis factor alpha production is regulated by MEK kinases", <i>Proc. Nat. Acad. Sci. USA</i> 94:6358-6363						
BY	Karin et al., 1997, "AP-1 function and regulation", <i>Curr Opin Cell Biol</i> 9:240-246.						
BZ	Koch et al., 1995, "Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1", <i>Nature</i> 376:517-519						
CA	Lange-Carter et al., 1993, "A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf.", <i>Science</i> 260:315-319						
CB	Li et al., 1996, "The Ras-JNK pathway is involved in shear-induced gene expression", <i>Mol. Cell. Biol.</i> 16:5947-5954						
CC	Li et al., 1999, "IKK1-deficient mice exhibit abnormal development of skin and skeleton", <i>Genes & Development</i> 13:1322-1328						
CD	Li et al., 1999, "Severe liver degeneration in mice lacking the IkappaB kinase 2 gene.", <i>Science</i> 284:321-324						
CE	Li et al., 1996, "Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells", <i>Science</i> 271: 1272-1276						
CF	Lin et al., 1995, "Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2", <i>Science</i> 268:286-289						
CG	Malinin et al., 1997, MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1", <i>Nature</i> 385:540-544						
CH	Manning et al., "Transcription inhibitors in inflammation", <i>Exp. Opin. Invest. Drugs</i> 6: 555-567 <i>no year</i>						
CI	Mercurio et al., 1999, "IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex", <i>Mol Cell Biol.</i> 19:1526-1538						
CJ	Mercurio et al., 1997, "IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation", <i>Science</i> 278:860-866						
CK	Milne et al., 1995, "p53 is phosphorylated <i>in vitro</i> and <i>in vivo</i> by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1", <i>J. Biol. Chem.</i> 270:5511-5518						
	Mohit et al., 1995, "p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system", <i>C.A. Neuron</i> 14:67-75						

AUG 28 2002		Nishina et al., 1997, "Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes", <i>J. Exp. Med.</i> 186:941-953
		Okamoto et al., 1997, "Selective activation of the JNK/AP-1 pathway in Fas-mediated apoptosis of rheumatoid arthritis synoviocytes", <i>Arth & Rheum</i> 40: 919-926
CN		Panet et al., 1995, "Regional differences in constitutive and induced ICAM-1 expression in vivo", <i>Am J Physiol.</i> 269:H1955-H1964
CO		Peet and Li, 1999, "kappaB kinases alpha and beta show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin", <i>Journal of Biological Chemistry</i> 274:32655-32661
CP		Pombo et al., 1994, "The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion", <i>J. Biol. Chem.</i> 269:26546-26551
CQ		Raitano et al., 1995, "The <i>Bcr-Abl</i> leukemia oncogene activates Jun kinase and requires Jun for transformation", <i>Proc. Nat. Acad. Sci USA</i> 92:11746-11750
CR		Sabapathy et al., 1999, "JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development", <i>Curr Biol</i> 9:116-125
CS		Su et al., 1994, "JNK is involved in signal integration during costimulation of T lymphocytes", <i>Cell</i> 77:727-736
CT		Swanek et al., 1997, "Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK", <i>Mol. Cell. Biol.</i> 17:6274-6282
CU		Szabo et al., "Altered cJUN expression: an early event in human lung carcinogenesis" <i>Cancer Res.</i> 56:305-315, 1996
CV		Takeda et al., 1999, "Limb and Skin Abnormalities in Mice Lacking IKK α ", <i>Science</i> 84:313-316, 1999
CW		Tanaka et al., 1999, "Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice", <i>immunity</i> 10:421-429
CX		Teramoto et al., 1996, "Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family", <i>J. Biol. Chem.</i> 271:27225-27228
CY		Tournier et al., 1997, "Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase", <i>Proc. Nat. Acad. Sci. USA</i> 94:7337-7342
CZ		Whitmarsh et al., 1996, "Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways", <i>J. Mol. Med.</i> 74:589-607
DA		Yan et al., 1994, "Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1", <i>Nature</i> 372:798-800
DB		Yang et al., 1998, "Differentiation of CD4 ⁺ T cells to Th1 cells requires MAP kinase JNK2", <i>Immunity</i> , 9:575-585
DC		Yaron et al., 1998, "Identification of the receptor component of the IkappaBalpha-ubiquitin ligase", <i>Nature</i> 396:590-594
DD		Yin et al., "Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney", <i>J. Biol. Chem.</i> 272:19943-19950
DE		Yujiri et al., 1998, "Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption", <i>Science</i> 282:1911-1914
DF		Zwacka et al., 1998, "Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation.", <i>Nature Medicine</i> 4:698-704

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
AUG 30 2002
TECH CENTER 1600/2900